Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005062893 - ANTI-CD52 ANTIBODY TREATMENT FOR DIABETES

Publication Number WO/2005/062893
Publication Date 14.07.2005
International Application No. PCT/US2004/043142
International Filing Date 22.12.2004
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 13/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
10of the bladder
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
C07K 16/2893
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2893against CD52
Applicants
  • GENZYME CORPORATION [US]/[US] (AllExceptUS)
  • ARTHAUD, Larry, E. [US]/[US] (UsOnly)
Inventors
  • ARTHAUD, Larry, E.
Agents
  • HIGHLANDER, Steven, L.
Priority Data
60/532,05922.12.2003US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CD52 ANTIBODY TREATMENT FOR DIABETES
(FR) TRAITEMENT ANTICORPS ANTI-CD52 POUR DIABETES
Abstract
(EN)
The present invention provides for the prevention and/or treatment of Type 1 diabetes mellitus with CD52 specific antibodies, e.g. CAMPATH-1H.
(FR)
La présente invention concerne la prévention et/ le traitement du diabète mellitus de type 1 avec des anticorps spécifiques CD52, notamment CAMPATH-1H.
Latest bibliographic data on file with the International Bureau